Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 36 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

9%

1 of 11 completed trials have results

Key Signals

13 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
25(71.4%)
Phase 2
9(25.7%)
Phase 3
1(2.9%)
35Total
Phase 1(25)
Phase 2(9)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (36)

Showing 20 of 36 trials
NCT05804045Phase 3Active Not Recruiting

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

Role: lead

NCT04192344Phase 1Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

Role: lead

NCT07010497Phase 2Recruiting

A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma

Role: collaborator

NCT07417189Phase 1Recruiting

A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )

Role: lead

NCT05441475Phase 2Enrolling By Invitation

A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients

Role: lead

NCT07327034Phase 2Recruiting

ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

Role: lead

NCT07301463Recruiting

A Study in Children With Achondroplasia

Role: lead

NCT07297875Phase 1Not Yet Recruiting

A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia

Role: lead

NCT07288957Phase 1Recruiting

A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors

Role: lead

NCT06306872Phase 1Completed

A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules

Role: lead

NCT07210996Phase 1Completed

A Study to Evaluate the Relative Bioavailability of Pimicotinib Capsules Containing Free Base in Different Proportions in Healthy Subjects

Role: lead

NCT04906434Phase 1Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

Role: lead

NCT05627063Phase 1Active Not Recruiting

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

Role: lead

NCT07164170Phase 2Not Yet Recruiting

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

Role: lead

NCT07126249Phase 1Completed

A Study to Evaluate the the Bioequivalence of Two Different Pimicotinib Capsules in Healthy Subjects

Role: lead

NCT06779253Phase 1Completed

A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects

Role: lead

NCT07007546Phase 1Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABSK061 Mini-tablets in Healthy Adult Participants

Role: lead

NCT06884072Phase 1Active Not Recruiting

A Study to Evaluate the Effect of a High-fat Meal on the Exposure of Pimicotinib Capsule in Healthy Subjects

Role: lead

NCT06896760Phase 1Not Yet Recruiting

A Mass Balance Study of [14C]ABSK011

Role: lead

NCT06322706Phase 1Completed

A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021

Role: lead